9/23/2018

Investigation of Jason Anderson, in the MPH, MT(ASCP) Field Product Clinical Specialist Laboratory

Objectives 1. Define hemolysis. 2. Distinguish between intrinsic and extrinsic hemolysis 3. Explain where in the body hemolysis can take place. 4. Describe how the body physiologically reacts when hemolysis is present. 5. Discuss hematological and biochemical tests, used in the laboratory investigation of hemolysis.

Copyright© 2018 Sysmex America, Inc. All rights reserved. 2

What is hemolysis?

• Premature breakdown of red blood cells • Where can hemolysis occur? • Within the macrophages of the Mononuclear Phagocyte System (MPS) • Within the blood vessels

1 9/23/2018

What is the normal aging process of red blood cells? • Average life span 120 days • What is the MPS? • RBCs have no nucleus – cannot • Mononuclear cells with pronounced phagocytic ability that are distributed synthesize new cellular extensively in lymphoid and other components organs. • Old/damaged RBCS are removed by macrophages within the MPS, most notably the Spleen • A small percentage break down within the circulation – cellular fragments are engulfed by macrophages.

Urobilinogen (urine) Process of normal RBC breakdown

Macrophage

RBC Protoporphyrin

Globin Reabsorbed Iron Amino acids

Amino acids Binds to transferrin Unconjugated bilirubin

Transported to the bone Bilirubin General protein synthesis marrow for incorporation glucoronides into erythroblasts (hgb formation (feces)

What causes hemolysis? • Some diseases and disease processes cause RBCs to breakdown prematurely • Normal response is for bone marrow to increase hematopoiesis • Causes of hemolysis can be broadly classified as being either intrinsic or extrinsic to the RBC • Intrinsic – occurs as a result of RBC defect • Most are hereditary • PNH is an exception – (acquired disorder) • Extrinsic – occurs as a result of ‘extracorpuscular’ or ‘environmental’ factors • patient’s own RBCs as well as any transfused RBCs will be affected as long as the causative factor remains in place

2 9/23/2018

Intrinsic causes of hemolysis

RBC defects Hereditary conditions RBC membrane defects 1. Hereditary Spherocytosis (HS) 2. Hereditary Elliptocytosis 3. Hereditary Stomatocytosis

Enzyme defects 1. Glucose-6-phosphate dehydrogenase deficiency (G6PD) 2. Pyruvate Kinase deficiency (PKD)

Hemoglobin defects 1. Sickle cell disease (HbS) 2. C 3. Thalassemia

Extrinsic causes of hemolysis • Non-Immune • Immune • Prosethetic heart valves • Idiopathic • TTP • Autoimmune • HUS • Leukemia/Lymphoma • DIC • Drugs • Preeclampsia/HELLP • Infections syndrome • Alloimmune • Infections • Hemolytic transfusion rxn • Malaria • Hemolytic disease of the newborn • Clostridia

Extrinsic causes of hemolysis – cont. • Chemical & physical agents • Certain drugs • Burns • Snake bites • Secondary to other disease • Liver and Renal disease • Mechanical stress • March hemoglobinuria

3 9/23/2018

Where does hemolysis take place?

• Within the Mononuclear Phagocyte System (MPS) • This is referred to as ‘ Extravascular Hemolysis ’

• Directly in the circulation • This is referred to as ‘ Intravascular Hemolysis ’

• Generally speaking, intravascular hemolysis is more acute and more severe

10

Intravascular hemolysis • RBCs broken down directly in the circulatory system. • Free Hgb and RBC Enzymes (LDH) are released in circulation.

• Hgb tetramer broken into dimers and immediately bound by which is saturated and immediately cleared by the liver • A low Haptoglobin level is a hallmark of Intravascular hemolysis.

• After Haptoglobin is saturated, excess free hgb is filtered in the kidneys and reabsorbed in the proximal tubules • Iron is recovered and converted into ferritin or hemosiderin • If rate of hemolysis is > renal tubule absorptive capacity, free hgb will be excreted in the urine (hemoglobinuria). Can be detected with urine strip.

Extravascular hemolysis

• Occurs when RBCs are phagocytosed by macrophages in the spleen, liver and bone marrow

• No free hgb is released into circulation • No hemoglobinemia/hemoglobinuria with extravascular hemolysis alone

• The breakdown of hgb within macrophages into its constituent components, and globin, occurs in the same manner as the normal aging process.

4 9/23/2018

The body’s reaction to hemolysis • Kidneys sensitive to changes in oxygenation of hgb. • Drop can occur due to a reduction in RBC mass (hemolysis or blood loss) • Release hormone Erythropoietin (EPO) • EPO is transported through plasma to BM where it accelerates erythropoiesis • EPO mechanism acts like a thermostat, increasing or decreasing erythropoiesis based on need

• When hemolysis is taking place, the bone marrow will increase the production of RBCs relative to the amount of EPO produced • If rate of RBC destruction is greater than ability for BM to compensate the individual will become anemic.

Detecting hemolysis in the lab • The approach in the dx of a hemolytic state involves: • Establishing that RBC destruction is accelerated • Establishing that erythropoiesis is increased

• The cause of hemolysis must be determined as well.

• If hemolytic is suspected the following should be performed • Complete blood count • Reticulocyte count • Peripheral blood smear examination

Tests reflecting increased RBC destruction

Test Intravascular hemolysis Extravascular hemolysis

1. Haptoglobin Decreased/depleted Normal

2. Serum bilirubin Increased unconjugated bilirubin Increased unconjugated bilirubin

3. for hgb Positive Negative

4. Urine Hemosiderin Positive Negative

5. LDH Increased Normal

6. test Decreased/depleted Normal

7. Urine test strip for Positive Positive

8. Schumm’s test for methemalbumin Positive Negative

5 9/23/2018

Test reflecting increased RBC production • Reticulocyte Count • Reticulocytes remain in the BM for ~2 days before being released into the peripheral blood • # of Reticulocytes in the peripheral blood provides information about BM activity (erythropoiesis) • In the event of hemolysis, the BM will try to compensate by upregulating erythropoetic activity. • Reticulocyte population can be counted via manual or automated methods.

Copyright© 2018 Sysmex America, Inc. All rights reserved. 16

Impact of artefactual hemolysis • The following practices can result in RBC lysis inside the collection tube ( in-vitro hemolysis) • Poor venipuncture technique • Exposure to excessively hot or cold temperatures (freezing) • Prolonged storage prior to analysis • It is important to be aware of this, as artefactual hemolysis may be very difficult to distinguish from intravascular hemolysis. In both cases on visual inspection, the plasma will have a reddish-brown color.

Copyright© 2018 Sysmex America, Inc. All rights reserved. 17

Laboratory findings in artefactual hemolysis

• The following findings suggest that in-vitro hemolysis has taken place: • A low RBC count and low HCT value with a normal HGB value. As a result, MCHC and MCH will appear raised. • No reticulocytosis even in the presence of RBC fragments. • Biochemical tests for intravascular hemolysis would be ‘negative’.

Copyright© 2018 Sysmex America, Inc. All rights reserved. 18

6 9/23/2018

RBC Morphology in Hemolytic

Copyright© 2018 Sysmex America, Inc. All rights reserved. 19

RBC morphology assoc. with hemolytic conditions

RBC feature Description Underlying mechanism Disease states

Basophilic Stippling Punctate basophilic Precipitated ribosomes Thalassemia and other inclusions anemias

Copyright© 2018 Sysmex America, Inc. All rights reserved. 20

RBC morphology assoc. with hemolytic conditions-cont.

RBC feature Description Underlying mechanism Disease states

Bite Cells Smooth semicircle Heinz bodies G6PD and drug-induced removed from the margin oxidant hemolysis of the cell

Copyright© 2018 Sysmex America, Inc. All rights reserved. 21

7 9/23/2018

RBC morphology assoc. with hemolytic conditions-cont.

RBC feature Description Underlying mechanism Disease states Small, discrete basophilic Nuclear remnant Hemolytic anemias Howell-Jolly bodies dense inclusions; usually singular

Copyright© 2018 Sysmex America, Inc. All rights reserved. 22

RBC morphology assoc. with hemolytic conditions-cont.

RBC feature Description Underlying mechanism Disease states

Microcytes Cells smaller than normal Abnormal hgb production Thalassemia (<7um)

Copyright© 2018 Sysmex America, Inc. All rights reserved. 23

RBC morphology assoc. with hemolytic conditions-cont.

RBC feature Description Underlying mechanism Disease states

Polychromatophilia Grey or blue hue Ribosome material Reticulocytosis, premature frequently seen in release of RBC from BM reticulocytes

Copyright© 2018 Sysmex America, Inc. All rights reserved. 24

8 9/23/2018

RBC morphology assoc. with hemolytic conditions-cont.

RBC feature Description Underlying mechanism Disease states

Schistocytes Distorted, fragemented Mechanical destruction Microangiopathic HA’s, cell, 2 or 3 pointed edges prosthetic valves, burns

Copyright© 2018 Sysmex America, Inc. All rights reserved. 25

RBC morphology assoc. with hemolytic conditions-cont.

RBC feature Description Underlying mechanism Disease states

Stomatocytes Mouth- or cuplike Membrane defect with Hereditary stomatocytosis, deformity abnormal cation Immune- permeability

Copyright© 2018 Sysmex America, Inc. All rights reserved. 26

RBC morphology assoc. with hemolytic conditions-cont.

RBC feature Description Underlying mechanism Disease states Target-like appearance, Relative membrane Thalassemia, Hb C Target Cells hypochromic with central excess due to decreased disease hgb hgb inside the cell

Copyright© 2018 Sysmex America, Inc. All rights reserved. 27

9 9/23/2018

RBC morphology assoc. with hemolytic conditions-cont.

RBC feature Description Underlying mechanism Disease states Sickle-shaped, pointed at Molecular aggregation of Sickle cell disorders Sickle Cells both ends hemoglobin S

Copyright© 2018 Sysmex America, Inc. All rights reserved. 28

RBC morphology assoc. with hemolytic conditions-cont.

RBC feature Description Underlying mechanism Disease states Spherical cell with dense Loss of surface membrane Hereditary Spherocytosis, Spherocytes hemoglobin and absent Immune-hemolytic anemia, central pallor; usually incompatible blood decreased in diameter transfusion

Copyright© 2018 Sysmex America, Inc. All rights reserved. 29

Copyright© 2018 Sysmex America, Inc. All rights reserved. 30

10 9/23/2018

Case study #1: history • A 59 y.o. woman reports to the ED with complaints of fatigue, shortness of breath and swelling in her right ankle. • She had just returned from an out of town trip and due to mechanical issues before takeoff, she had spent 11 hours on the plane. • Upon examination she was found to be hypoxemic with a saturation of 88%. Her d-dimer was elevated and CT angiogram of the thorax revealed a left segmental pulmonary emboli. A CBC was also performed and results revealed a hemoglobin of 7.2 g/dl. Patient was referred to local hematology/oncology center for a hematology consultation.

Case study #1: hematology results

Copyright© 2018 Sysmex America, Inc. All rights reserved. 32

Case study #1: hematology results - cont.

RETICULOCYTE – Final Value Unit Reference Range

Retic % 17.9 High % 0.6 –2.0

Retic Absolute 0.3409 High x10^6uL 0.025 –0.102

Immature Retic Fraction 40.90 High % 1.1 –15.9

Reticulated Hgb 37.1 High pg 28.2 –36.6

Questions 1. Based on what we know so far, can we conclude that this is a hemolytic anemia? 2. What can we gather from the test results thus far?

Copyright© 2018 Sysmex America, Inc. All rights reserved. 33

11 9/23/2018

Case study #1: hematology results - cont. • Manual differential/smear review was performed

• What do you see? Spherocytes

Copyright© 2018 Sysmex America, Inc. All rights reserved. 34

Case study #1: biochemistry results • CMP , LDH, and Haptoglobin was ordered • All chemistry results were within the normal reference range except for the following

Result Value Units Range

Glucose 117 High Mg/dL 65 -100

Total Bilirubin 2.4 High Mg/dL 0.2 -1.0

LDH 771 High U/L 120 -280

Haptoglobin < 10 Low Mg/dL 30 -200

Copyright© 2018 Sysmex America, Inc. All rights reserved. 35

Case study #1: diagnosis

• Additional medical history reveals patient has Rheumatoid Arthritis (RA) and is taking Methotrexate as part of their treatment plan

• Diagnosis? Autoimmune Hemolytic Anemia

• People with one type of autoimmune disease, such as RA, are prone to develop another type of autoimmune disease. Drugs such as Methotrexate can also trigger an AIHA

Copyright© 2018 Sysmex America, Inc. All rights reserved. 36

12 9/23/2018

Case study #1: Treatment • Patient was treated with Prednisone and blood transfusions • Weekly lab tests were performed to monitor progress

• Patient did not tolerate the prednisone very well, so her treatment was switched to Rituximab which resulted in a remission state of the patient’s AIHA

Copyright© 2018 Sysmex America, Inc. All rights reserved. 37

Case study #2: history • 39 y.o male admitted to the hospital with complaints of epigastric pain, nausea and vomiting. • CT scan revealed mass in the pancreatic head plus liver lesions • Biopsy positive for adenocarcinoma of the pancreas • Patient started on Folfirinox as palliative chemotherapy • After 2 cycles of chemo, bilirubin increased and CT scan showed disease progression • Chemotherapy switched to Gemzar and Abraxane

Copyright© 2018 Sysmex America, Inc. All rights reserved. 38

Case study #2: history – cont.

• After the 1 st cycle of the new treatment regimen, pt’s hemoglobin dropped significantly. • Lab tests were drawn including a CBC with manual diff, retic panel, CMP, LDH, Haptoglobin and Iron studies

Copyright© 2018 Sysmex America, Inc. All rights reserved. 39

13 9/23/2018

Case study #2: hematology results

Copyright© 2018 Sysmex America, Inc. All rights reserved. 40

Case study #2: hematology results – cont.

Result Units Ref. Range

41 Copyright© 2018 Sysmex America, Inc. All rights reserved.

Case study #2: hematology results - cont. • Manual differential/smear review was performed

• What do you see? Schistocytes

Copyright© 2018 Sysmex America, Inc. All rights reserved. 42

14 9/23/2018

Case study #2: hematology results - cont.

Copyright© 2018 Sysmex America, Inc. All rights reserved. 43

Case study #2: biochemistry results • CMP and Iron study results were unremarkable aside from a slightly elevated BUN, AST and moderately elevated ALP

• What is the Haptoglobin and LDH ‘telling us’?

Copyright© 2018 Sysmex America, Inc. All rights reserved. 44

Case study #2: diagnosis

• Diagnosis? Microangiopathic Hemolytic Anemia (MAHA)

• Additional testing done to try to find the cause of the MAHA including: • Enteric Pathogen screen, ADAMTS13 and G6PD. All were ruled out.

• Conclusion was MAHA was drug related, most likely the Gemzar as there is documentation that hemolytic anemia can be a side effect of this drug.

Copyright© 2018 Sysmex America, Inc. All rights reserved. 45

15 9/23/2018

Lab investigation of hemolysis - summary

• Artefactual hemolysis can mimic intravascular hemolysis. The laboratory must make every effort to identify its presence • An elevated reticulocyte count is essential for the diagnosis of hemolysis as this signals increased RBC production. • RBC morphology is informative in determining the cause of hemolysis. • Biochemical tests of hemolysis confirm the presence of RBC breakdown and are useful in distinguishing between intravascular and extravascular hemolysis.

Copyright© 2018 Sysmex America, Inc. All rights reserved. 46

References

• Sysmex Europe (2015, October 22). SEED: Laboratory Investigation of Haemolysis. Retrieved 9/4/18 from https://www.sysmex- europe.com/fileadmin/media/f100/SEED/Sysmex_SEED_Laboratory_investigation_of_haemol ysis.pdf

• U.S National Library of Medicine (2016, November 23). Mononuclear Phagocyte System MeSH Descriptor Data 2018. Retrieved 9/4/18 from https://meshb.nlm.nih.gov/record/ui?name=Mononuclear%20Phagocyte%20System

• Bain, B.J. (2005, August 4). Diagnosis from the Blood Smear. Retrieved 9/4/18 from https://www.nejm.org/doi/full/10.1056/NEJMra043442

16